GLOBAL UPDATE – CLINICAL TRIAL NEWS 
Neurogene Inc. announced that its Phase 1/2 Trial of NGN-101 Gene Therapy for the treatment of CLN5 Batten disease is now fully enrolled (n=6), with plans to provide interim clinical data and a regulatory update in the first quarter of 2025. Read our global update here: https://ow.ly/HSSE50SW7Ie
Neurogene Inc. announced that its Phase 1/2 Trial of NGN-101 Gene Therapy for the treatment of CLN5 Batten disease is now fully enrolled (n=6), with plans to provide interim clinical data and a regulatory update in the first quarter of 2025. Read our global update here: https://ow.ly/HSSE50SW7Ie